NCT04346719

Brief Summary

High-frequency alternating currents of greater than 1 kHz applied on peripheral nerves has been used in animal studies to produce a motor nerve block. It has been evidenced that frequencies higher than 5 kHz are necessary to produce a complete peripheral nerve block in primates, whose nerve thickness is more similar to humans.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jun 2020

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 2, 2020

Completed
13 days until next milestone

First Posted

Study publicly available on registry

April 15, 2020

Completed
2 months until next milestone

Study Start

First participant enrolled

June 1, 2020

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 17, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 17, 2020

Completed
Last Updated

November 18, 2020

Status Verified

November 1, 2020

Enrollment Period

6 months

First QC Date

April 2, 2020

Last Update Submit

November 17, 2020

Conditions

Keywords

high-frequency alternating currentnerve blocksomatosensory thresholdmotor thresholdpercutaneous electrical stimulation

Outcome Measures

Primary Outcomes (26)

  • Antidromic median sensory nerve action potential

    The recording electrodes were placed on the second finger and the stimulus will be applied on the median nerve (above the elbow joint). The stimulus will consist of a train of 10 pulses (100 μs width), applied at supramaximal stimulation, presented at 1 Hz (DS7A, Digitimer Ltd). Negative peak latency (NPL), positive peak latency (PPL), and peak-to-peak amplitude (PPA) will be registered with a specific software (Signal software, CED).

    Baseline at 0 minutes

  • Tactile Threshold

    The tactile threshold will be measured with Von Frey filaments and will be expressed in millinewton

    Baseline at 0 minutes

  • Oscillation Frequency of tissue assessed by MyotonPro

    This outcome measure is obtained by a device named MyotonPro. The frequency of the damped oscillations characterizes the muscle tone. The muscle will be assessed is opponens pollicis muscle

    Baseline at 0 minutes

  • Stiffness of tissue assessed by MyotonPro

    This outcome measure is obtained by a device named MyotonPro. Stiffness reflects the resistance of the muscle to the force deforming the muscle. The muscle will be assessed is opponens pollicis muscle

    Baseline at 0 minutes

  • Decrement (elasticity) of tissue assessed by MyotonPro

    This outcome measure is obtained by a device named MyotonPro. The logarithmic decrement of the damping oscillations characterizes muscle elasticity which is the ability of the muscle to restore its initial shape after contraction. The muscle will be assessed is opponens pollicis muscle

    Baseline at 0 minutes

  • Pressure Pain Threshold

    The PPT will be measured with an algometer and will be expressed in Newtons

    Baseline at 0 minutes

  • Muscle strength

    Muscle strength will be measured with a dynamometer and will be expressed in Kgs.

    Baseline at 0 minutes

  • Tactile Threshold

    The tactile threshold will be measured with Von Frey filaments and will be expressed in millinewton

    During treatment at 15 minutes

  • Oscillation Frequency of tissue assessed by MyotonPro

    This outcome measure is obtained by a device named MyotonPro. The frequency of the damped oscillations characterizes the muscle tone. The muscle will be assessed is opponens pollicis muscle

    During treatment at 15 minutes

  • Stiffness of tissue assessed by MyotonPro

    This outcome measure is obtained by a device named MyotonPro. Stiffness reflects the resistance of the muscle to the force deforming the muscle. The muscle will be assessed is opponens pollicis muscle

    During treatment at 15 minutes

  • Decrement (elasticity) of tissue assessed by MyotonPro

    This outcome measure is obtained by a device named MyotonPro. The logarithmic decrement of the damping oscillations characterizes muscle elasticity which is the ability of the muscle to restore its initial shape after contraction. The muscle will be assessed is opponens pollicis muscle

    During treatment at 15 minutes

  • Pressure Pain Threshold

    The PPT will be measured with an algometer and will be expressed in Newtons

    During treatment at 15 minutes

  • Antidromic median sensory nerve action potential

    The recording electrodes were placed on the second finger and the stimulus will be applied on the median nerve (above the elbow joint). The stimulus will consist of a train of 10 pulses (100 μs width), applied at supramaximal stimulation, presented at 1 Hz (DS7A, Digitimer Ltd). Negative peak latency (NPL), positive peak latency (PPL), and peak-to-peak amplitude (PPA) will be registered with a specific software (Signal software, CED).

    Immediately after treatment at 20 minutes

  • Tactile Threshold

    The tactile threshold will be measured with Von Frey filaments and will be expressed in millinewton

    Immediately after treatment at 20 minutes

  • Oscillation Frequency of tissue assessed by MyotonPro

    This outcome measure is obtained by a device named MyotonPro. The frequency of the damped oscillations characterizes the muscle tone. The muscle will be assessed is opponens pollicis muscle

    Immediately after treatment at 20 minutes

  • Stiffness of tissue assessed by MyotonPro

    This outcome measure is obtained by a device named MyotonPro. Stiffness reflects the resistance of the muscle to the force deforming the muscle. The muscle will be assessed is opponens pollicis muscle

    Immediately after treatment at 20 minutes

  • Decrement (elasticity) of tissue assessed by MyotonPro

    This outcome measure is obtained by a device named MyotonPro. The logarithmic decrement of the damping oscillations characterizes muscle elasticity which is the ability of the muscle to restore its initial shape after contraction. The muscle will be assessed is opponens pollicis muscle

    Immediately after treatment at 20 minutes

  • Pressure Pain Threshold

    The PPT will be measured with an algometer and will be expressed in Newtons

    Immediately after treatment at 20 minutes

  • Muscle strength

    Muscle strength will be measured with a dynamometer and will be expressed in Kgs.

    Immediately after treatment at 20 minutes

  • Antidromic median sensory nerve action potential

    The recording electrodes were placed on the second finger and the stimulus will be applied on the median nerve (above the elbow joint). The stimulus will consist of a train of 10 pulses (100 μs width), applied at supramaximal stimulation, presented at 1 Hz (DS7A, Digitimer Ltd). Negative peak latency (NPL), positive peak latency (PPL), and peak-to-peak amplitude (PPA) will be registered with a specific software (Signal software, CED).

    Immediately after treatment at 30 minutes

  • Tactile Threshold

    The tactile threshold will be measured with Von Frey filaments and will be expressed in millinewton

    Immediately after treatment at 30 minutes

  • Oscillation Frequency of tissue assessed by MyotonPro

    This outcome measure is obtained by a device named MyotonPro. The frequency of the damped oscillations characterizes the muscle tone. The muscle will be assessed is opponens pollicis muscle

    Immediately after treatment at 30 minutes

  • Stiffness of tissue assessed by MyotonPro

    This outcome measure is obtained by a device named MyotonPro. Stiffness reflects the resistance of the muscle to the force deforming the muscle. The muscle will be assessed is opponens pollicis muscle

    Immediately after treatment at 30 minutes

  • Decrement (elasticity) of tissue assessed by MyotonPro

    This outcome measure is obtained by a device named MyotonPro. The logarithmic decrement of the damping oscillations characterizes muscle elasticity which is the ability of the muscle to restore its initial shape after contraction. The muscle will be assessed is opponens pollicis muscle

    Immediately after treatment at 30 minutes

  • Pressure Pain Threshold

    The PPT will be measured with an algometer and will be expressed in Newtons

    Immediately after treatment at 30 minutes

  • Muscle strength

    Muscle strength will be measured with a dynamometer and will be expressed in Kgs.

    Immediately after treatment at 30 minutes

Secondary Outcomes (6)

  • Baseline nerve temperature

    Baseline at 0 minutes, at 15 minutes, immediately after treatment at 20 minutes, and immediately after treatment at 30 minutes

  • Baseline flux temperature

    Baseline at 0 minutes, at 15 minutes, immediately after treatment at 20 minutes, and immediately after treatment at 30 minutes

  • Numerical Discomfort Rate Score

    After the intervention at 35 minutes

  • Numerical Pain Rate Score

    After the intervention at 35 minutes

  • Number of participants with intervention-related adverse effects

    After the intervention at 35 minutes

  • +1 more secondary outcomes

Study Arms (3)

10 kHz stimulation

EXPERIMENTAL

Transcutaneous application of high frequency electrical current at 10 kHz over the median nerve for a 20 minutes session. The intensity of the current will increase until participants report a "strong but comfortable" sensation, just below motor threshold.

Device: 10 kHz stimulation (Myomed 932, Enraf-Nonius)

20 kHz stimulation

EXPERIMENTAL

Transcutaneous application of high frequency electrical current at 20 kHz over the median nerve for a 20 minutes session. The intensity of the current will increase until participants report a "strong but comfortable" sensation, just below motor threshold.

Device: 20 kHz stimulation (Myomed 932, Enraf-Nonius)

Sham stimulation

SHAM COMPARATOR

Electrodes are placed over the median nerve for 20 minutes in the same manner as experimental group but will be applied a sham electrical stimulation increasing the current intensity during the first 30 seconds.

Device: Sham stimulation (Myomed 932, Enraf-Nonius)

Interventions

A charge-balanced, symmetric, biphasic sinusoidal current without modulation will be delivered at a frequency of 10 kHz. The stimulation intensity will be defined as that sufficient to produce a "strong but comfortable" sensation, just below motor threshold, over the median nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft,Netherlands)

10 kHz stimulation

A charge-balanced, symmetric, biphasic sinusoidal current without modulation will be delivered at a frequency of 20 kHz. The stimulation intensity will be defined as that sufficient to produce a "strong but comfortable" sensation, just below motor threshold, over the median nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft,Netherlands)

20 kHz stimulation

Sham stimulation will be delivered at a frequency of 10 kHz only during the first 30 seconds.

Sham stimulation

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Healthy volunteers
  • Ability to perform all clinical tests and understand the study process, as well as obtaining informed consent.
  • Tolerance to the application of electrotherapy.
  • That they have not diagnosed any pathology.
  • They do not present a contraindication to puncture and / or the application of electric currents.

You may not qualify if:

  • Neuromuscular disease.
  • Epilepsy.
  • Trauma, surgery or pain affecting the upper limb
  • Osteosynthesis material in the upper limb.
  • Diabetes.
  • Cancer.
  • Cardiovascular disease.
  • Pacemaker or other implanted electrical device.
  • Take any drug (NSAIDs, corticosteroids, antidepressants, analgesics, antiepileptics, ...) during the study and in the previous 7 days.
  • Presence of tattoos or other external agent introduced into the treatment or assessment area.
  • Pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Castilla-La Mancha University

Toledo, 45071, Spain

Location

Study Officials

  • Juan Avendaño-Coy, PhD

    Castilla-La Mancha University

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 2, 2020

First Posted

April 15, 2020

Study Start

June 1, 2020

Primary Completion

November 17, 2020

Study Completion

November 17, 2020

Last Updated

November 18, 2020

Record last verified: 2020-11

Data Sharing

IPD Sharing
Will not share

Locations